Home HealthCare Juniper Pharmaceuticals declared Appointment of Jeffrey Young as Chief Financial Officer

Juniper Pharmaceuticals declared Appointment of Jeffrey Young as Chief Financial Officer


News: Juniper Pharmaceuticals Inc (NASDAQ:JNP) belongs to Healthcare sector and Drugs – Generic industry. Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (“Juniper” or the “Organization”), a ladies’ wellbeing therapeutics organization, recently declared the arrangement of Jeffrey Young as Chief Financial Officer, Treasurer and Secretary viable January 1, 2017.

Mr. Youthful brings more than 20 years of money related authority in the life sciences segment to Juniper. He most as of late served as Chief Financial Officer and Treasurer of OvaScience, a worldwide richness organization concentrated on new treatment alternatives for ladies.

“Jeff’s differentiated money related involvement with both improvement stage and business organizations and profound information of the ladies’ wellbeing part will be a gigantic advantage for Juniper as we construct and propel our arrangement of item contender to address neglected and underserved restorative needs in ladies’ wellbeing,” said Alicia Secor, Juniper’s President and Chief Executive Officer. “We are excited to welcome Jeff to the administration group, and anticipate his commitments.”

“I am eager to join Juniper at this imperative time in the Company’s development direction,” said Mr. Youthful. “Juniper’s Crinone® establishment and JPS division give a strong money related establishment to the Company as it advances its IVR pipeline and seeks after extra chances to fabricate a main ladies’ wellbeing organization. I anticipate working with the group to accomplish Juniper’s monetary and key goals.”

Mr. Youthful will succeed George O. Elston, the Company’s active Chief Financial Officer, Treasurer and Secretary, will’s identity venturing down toward the end of the year.

“We value George’s money related initiative in the course of recent years,” Ms. Secor proceeded. His numerous commitments incorporate the late adaptation of the U.S. Crinone eminence stream with Allergan, which fortified our monetary record. We wish him well in his future attempts.”

Amid his two-year residency at OvaScience, Mr. Youthful drove the organization’s gathering pledges endeavors and universal assessment procedure. He was beforehand the Chief Financial Officer and Treasurer of Transmedics, an engineer of medicinal gadgets for the support and transport of organs amongst contributors and beneficiaries. Prior to that, Mr. Youthful served as Chief Financial Officer and Treasurer at Lantheus Medical Imaging, where he drove and dealt with numerous obligation offerings. He joined Lantheus from Critical Therapeutics, where he was Chief Accounting Officer. At a very early stage in his profession, he worked in different fund parts at PerkinElmer, Inc., and PriceWaterhouseCoopers LLP. Mr. Youthful is a Certified Public Accountant and holds a B.S. in Business Administration from Georgetown University.

Regarding Mr. Youthful’s going into work with Juniper, he will get a business actuation give to buy 170,000 shares of Juniper’s basic stock at a practice value equivalent to the market shutting cost on January 3, 2017. The investment opportunity honor will have an existence of seven years, and will vest at the rate of one-quarter every year on each of the initial four commemorations of his business. The investment opportunity honor will be allowed without stockholder endorsement as an actuation material to Mr. Youthful going into work with Juniper as per NASDAQ Listing Rule 5635(c)(4).

Summary: Juniper Pharmaceuticals, Inc. is centered around creating therapeutics that address neglected restorative needs in ladies’ wellbeing. The Company is propelling a pipeline of restrictive item applicants that influence its separated intravaginal ring innovation and when suitable the 505(b)(2) administrative pathway. Focused on item improvement speculations are empowered by Juniper’s center working business: the Crinone® (progesterone gel) establishment and Juniper Pharma Services, which gives top of the line charge to administration pharmaceutical advancement and clinical trials assembling to customers.